AEON Biopharma, Inc. 8-K

What Happened

• AEON Biopharma, Inc. held its Annual Meeting of Stockholders on June 17, 2026 and filed a Form 8‑K (Item 5.07) reporting the certified vote results.
• Stockholders elected Marc Forth and Seongsoo Park as Class III directors for terms expiring in 2029. Vote counts: Marc Forth — For 13,297,322; Withheld 27,738; Broker non-vote 8,197,073. Seongsoo Park — For 13,117,299; Withheld 207,761; Broker non-vote 8,197,073.
• Stockholders also ratified KPMG LLP as AEON’s independent registered public accounting firm for the 2026 fiscal year: For 21,502,418; Against 18,217; Abstain 1,498; no broker non-votes reported.

Key Details

• Meeting date: June 17, 2026; proxy previously filed April 29, 2026.
• Elected directors’ terms end at the 2029 annual meeting.
• KPMG LLP ratified as auditor for fiscal year ending December 31, 2026.
• Results were certified by the company’s inspector of elections; Form 8‑K signed by CEO Robert Bancroft on June 17, 2026.

Why It Matters

• The re-election of two directors maintains the current board composition through 2029, affecting corporate governance and strategic oversight.
• Ratification of KPMG confirms continuity of the company’s independent auditor for 2026, relevant to future financial reporting and audit processes.
• These are procedural, governance items disclosed to inform investors about leadership and auditor approvals—no operational or financial performance metrics were reported in this filing.